Fig. 2: Different patterns of immune cell reconstitution in myeloma patients post cilta-cel vs. ide-cel CAR-T. | Nature Communications

Fig. 2: Different patterns of immune cell reconstitution in myeloma patients post cilta-cel vs. ide-cel CAR-T.

From: Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

Fig. 2

A Dots indicate absolute counts of white blood cells (WBC), neutrophils, lymphocytes and conventional T cells in patients post cilta-cel (blue; N = 23) or ide-cel (red; N = 16) at the time of cell infusion (D0) and the time of the patient’s individual CAR T peak. The dotted line and the solid lines indicate median baseline and peak levels, respectively. B Absolute CAR T cell counts in patients post cilta-cel (blue; N = 23) or ide-cel (red; N = 16) at the time of cell infusion (D0) and the time of the patient’s individual CAR T peak. C Bar graphs on the left show absolute peak levels of conventional T cells and bar graphs on the right show absolute peak levels of CAR T cells in patients post cilta-cel (blue; N = 23) or ide-cel (red; N = 16), respectively. D Orange bar graphs show absolute counts of CAR T across cilta-cel (N = 23) or ide-cel (N = 16) patients who did or did not receive steroids post CAR T infusion. All bar graphs indicate median values with 95% confidence intervals (CI). Statistical differences between groups were calculated using a two-sided Mann-Whitney U test. Source data are provided as a Source Data file.

Back to article page